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ABSTRACT 
CURCUMIN REACTIVATES EPIGENETICALL Y SILENCED TUMOR 
SUPPRESSOR GENE TISSUE FACTOR PATHWAY INHIBITOR-2 IN 
HEPATOCELLULAR CARCINOMA CELLS 
Akshata Moghe 
July 1,2010 
Hepatocellular carcinoma (HCC) is the fifth most common cancer 
worldwide and the third most fatal, with a rising incidence in the US as a result of 
the increase in alcoholic liver disease and obesity. Current therapeutic strategies 
are unsatisfactory with poor treatment outcomes and efficacious therapies are 
acutely needed for better management of this deadly disease. Curcumin, a 
phenolic compound from the rhizome of the plant Curcuma longa has been 
shown to inhibit growth and induce cell death in various types of cancer cells 
including HCC. However, the anti-HCC mode of action of curcumin has not yet 
been elucidated. 
In HCC, aberrant promoter methylation and histone deacetylation are 
implicated in the inactivation of tumor suppressor genes which has a significant 
impact on carcinogenesis. Tissue factor pathway inhibitor-2 (TFPI-2), a Kunitz-
type serine protease inhibitor, is a tumor suppressor gene that is frequently 
epigenetically silenced in human HCC and HCC cell lines. Restoration of TFPI-2 
expression in tumor tissue has been shown to not only inhibit invasion, tumor 
IV 
growth, metastasis and angiogenesis but also induce apoptosis. We examined 
the effects of curcumin on tumor suppressor genes in HCC and observed robust 
reactivation of TFPI-2 in HepG2 cells upon curcumin treatment. We confirmed 
that TFPI-2 was under epigenetic control in HepG2 cells by using demethylating 
agent 5-Aza-2'deoxycytidine (5-AZA) and histone deacetylase inhibitor 
trichostatin A (TSA), both of which induced gene expression. Further, we 
investigated the epigenetic modifications at the TFPI-2 promoter and the 
alterations induced by curcumin in these epigenetic states. Histone H3 
acetylation at the transcription factor binding sites of the TFPI-2 promoter region 
was increased by curcumin and correlated with the induction of gene expression. 
The reactivation of TFPI-2 also corresponded with a decrease in cell 
invasiveness and increase in cell death in HepG2 cells. Overall, our data strongly 
suggest that curcumin can reverse the epigenetic alterations at the TFPI-2 
promoter and thus, reactivate this silenced tumor suppressor gene. These results 
support a potential therapeutic role for curcumin in the management of HCC. 
v 
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CHAPTER I 
INTRODUCTION 
Hepatocellular Carcinoma (HCCl 
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the 
world1-2 and the third most common cause of cancer-related mortality1, 3. Every 
year, between 500,000 and 1000,000 new cases of HCC are detected, and 
almost all of the victims die of the disease. HCC has a higher incidence in 
developing countries, especially in Sub-Saharan Africa and South Asia, due to 
the increased prevalence of viral hepatitis in these regions. However, this trend is 
now changing and there has been an alarming rise in the incidence of HCC in 
economically developed nations like Japan, Western Europe and the United 
States in the past few years2. In the United States, in addition to Hepatitis C viral 
(HCV) infection, the growing epidemics of alcoholic liver disease (ALD), obesity 
and non-alcoholic steatohepatitis (NASH) have contributed to the rapid rise in 
HCC incidence. Liver cirrhosis is a premalignant condition that greatly increases 
the risk of HCC, and is common in the USA2. It is expected that the incidence of 
HCC will only continue to rise in the coming years as latent HCV infections come 
to the fore and as more and more cases of ALD and NASH 
1 
emerge and progress to cirrhosis2-3. The reason for the high mortality associated 
with HCC is that the treatment modalities available today are minimally effective 
at best. The best treatment option is liver transplantation, which is not only 
expensive but also complicated in the setting of liver cirrhosis, a condition 
invariably present in these patients. Moreover, most patients are diagnosed at a 
late stage in the disease, and their cancers are not amenable to transplantation. 
Other surgical interventions such as liver resection, percutaneous ethanol 
injection, radiofrequency ablation, transarterial embolization and 
chemoembolization have been tried with unsatisfactory outcomes. Adjuvant 
chemotherapy with various chemotherapeutic agents such as doxorubicin, 
cisplatin, fluorouracil and interferon also yields little survival benefit. Recently, 
Sorafenib, a tyrosine protein kinase inhibitor, was approved for use in HCC but 
its efficacy and toxicity is still being investigated in clinical trials. If left untreated, 
HCC progresses rapidly to death within 6-8 months even when diagnosed early. 
Patient prognosis is poor and the 5-year survival rate utterly dismal at less than 5 
percent4. As a result, there is an urgent need for the development or discovery of 
a novel, effective therapy for the management of HCC. 
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Pathogenesis of HCC : relevance to tumor suppressor genes 
An understanding of the process of hepatocellular carcinogenesis is critical in 
order to define pertinent molecular targets for therapy. Until now, HCC had been 
linked to increases in allelic losses, chromosomal changes, gene mutations and 
alterations in molecular cellular pathways5. It is now recognized that in addition to 
the known genetic alterations of mutations and deletions, epigenetic alterations 
can also playa major role in tumorogenesis5. In HCC, as in other cancers, 
aberrant DNA methylation and specific histone modifications are implicated in the 
development and progression of the disease5-7 . Aberrant DNA methylation 
occurs in the form of global hypomethylation and regional hypermethylation of 
CpG islands. The global hypomethylation results in the activation of 
protooncogenes. Regional hypermethylation in the promoter regions of tumor 
suppressor (TS) genes leads to their transcriptional silencing and inactivation6,8. 
Several TS genes such as TFPI-2, RASSF1A, P16, P15 and GADD45 have been 
found to be frequently epigenetically silenced through promoter hypermethylation 
in HCC8-13. 
3 
Hepatocellular carcinogenesis 
Normal hepatocytes 
Epigenetically 
reprogrammed hepatocytes 
Hepatocellular 
Carcinoma 
Alterations in cellular epigenome: 
• Global DNA hypomethylation 
• Regional hypermethylation at the 
promoters of tumor suppressor genes 
• Aberrant histone modifications 
Compromised genomic stability 
Fig. 1 Epigenetic mechanisms of carcinogenesis in HCC 
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Tissue Factor Pathway Inhibitor-2 (TFPI-2) 
Amongst the identified TS genes, Tissue factor pathway inhibitor-2 
(TFPI-2) is significantly underexpressed14 in approximately 90 percent of 
primary HCCs when compared to their corresponding non-tumorous 
Iivers9. Wong et. al. (2007) studied the gene expression profiles of several 
candidate genes in HCC by microarray analysis and detected frequent 
inactivation of TFPI-2 in several human HCC cell lines and human HCC samples. 
Expression of TFPI-2 in HCC cell lines could be robustly restored by treatment 
with known epigenetic modulators such as 5-Aza-2-deoxycytidine (5-AzadC, a 
DNA methyltransferase inhibitor) and Trichostatin A (TSA, a histone deacetylase 
inhibitor) , which implied that the gene was indeed under epigenetic control9 . 
TFPI-2 is a Kunitz-type serine proteinase inhibitor. Previously designated 
as placental protein 5, it inhibits a broad range of serine proteinases and plays an 
important role in the regulation of extracellular matrix degradation and 
remodeling 15. TFPI-2 inhibits plasmin and trypsin activity and reduces cellular 
invasiveness of tumors. Reduced expression of TFPI-2 has been associated with 
several patho-physiological processes such as inflammation, angiogenesis, 
atherosclerosis, retinal degeneration and tumor growth and metastasis15. 
Besides HCC, TFPI-2 is inactivated in many other tumors, including esophageal, 
pancreatic, gastric, colon and breast cancers 16-20. Overexpression of TFPI-2 or 
upregulation of the reduced expression of TFPI-2 has the potential to limit tumor 
growth by inhibiting angiogenesis, cellular proliferation and cellular invasiveness 
of tumor cells21 -22 . Restoration of TFPI-2 has also been shown to trigger 
5 
apoptosis through a caspase-mediated mechanism in a human glioblastoma cell 
ABERRANT CpG ISLAND METHYLATION 
and/or 
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at the TFPI-2 promoter 
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Fig.2 Proposed epigenetic mechanisms that silence tumor suppressor 
gene TFPI-2 in HCC and the implications of inactivation of the gene 
Modified from Chand HS et al. 15 
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Importantly, in HCC as well, ectopic overexpression of TFPI-2 has been 
shown to significantly suppress proliferation and invasiveness of tumor cells9 . 
Taken together, these data strongly imply that loss of TFPI-2 expression is 
critical to the establishment and progression of HCC. Hence, TFPI-2 is an 
important target tumor suppressor gene in the treatment and control of 
HCC. 
Curcumin as an epigenetic modulator 
Curcumin, the phenolic compound from the rhizome of the plant Curcuma 
Longa (turmeric, yellow curry powder) has been used for centuries in ancient 
medicine to treat various diseases. In recent years, curcumin (diferuloylmethane) 
has been extensively characterized to define the mechanisms underlying its 
innumerable beneficial properties. Curcumin displays a plethora of favorable 
effects, including anti-inflammatory, anti-oxidant, anti-proliferative and pro-
apoptotic effects24-25 . Its anti-inflammatory effects are mediated through the 
inhibition of inflammatory transcription factors (such as nuclear factor K8), 
enzymes (such as cyclooxygenase-2 and 5-lipoxygenase) and cytokines (such 
as tumor necrosis factor, interleukin 1 and interleukin 6)25. Since most chronic 
diseases involve inflammation, curcumin has been used to treat a myriad of 
cardiovascular, pulmonary, neurological and metabolic diseases. The anti-
tumorigenic properties of curcumin are being investigated in many cancers26 and 
curcumin is also being tested in human clinical trials for the treatment of colon 
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and pancreatic cancers27. Importantly, curcumin has been shown to possess 
anti-HCC properties in in vitro and in animal studies28-29 . However, its exact 
mechanism of action in the control of HCC is still not well-elucidated. 
In our experiments, we confirmed that curcumin kills HCC cells using 
HepG2, a well characterized HCC cell line. We also examined the effect of 
curcumin on TFPI-2 in HepG2 cells and our preliminary data show that curcumin 
was able to significantly reactivate TFPI-2 gene expression, similar to the effects 
of the epigenetic modulators 5-Aza-2-deoxycytidine and Trichostatin A. These 
results support a potential role for curcumin as an epigenetic modulator in its 
anti-HCC action. Curcumin has recently been shown to cause epigenetic 
alterations through both, histone modifications and DNA methylation3o. However, 
these alterations induced by curcumin are only beginning to be studied. 
Hypothesis 
The effects of curcumin appear to be complex and context-dependent as 
curcumin supports histone acetylation in some cases and histone deacetylation 
in others31 -32• Moreover, there is no systematic study as yet investigating the role 
of curcumin as an epigenetic modulator in HCC cells. Based on our preliminary 
data, we propose that curcumin induces epigenetic modifications in HCC cells, 
particularly with respect to tumor suppressor genes. Specifically, we hypothesize 
that curcumin induces de-repression of the epigenetically silenced tumor 
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suppressor gene TFPI-2 in hepatocellular carcinoma (HCC) cells and that 
this effect is a significant component of its anti-HCC action. 
9 
Reagents 
CHAPTER II 
MATERIALS AND METHODS 
Curcumin was purchased from Biomol (Plymouth Meeting, PAl. 5-Aza -2' 
deoxycytidine, Trichostatin A and dimethyl sulfoxide (DMSO) were purchased 
from Sigma-Aldrich (St. Louis, MO). Fetal bovine serum was purchased from 
Atlanta Biologicals (Norcross, GA). DMEM, penicillin, streptomycin and TRlzol® 
were obtained from Invitrogen (Carlsbad, CA). All RT-PCR reagents were 
purchased from Applied Biosystems (Foster City, CA). MTT (Thiazolyl Blue 
Tetrazolium Bromide) was obtained from Sigma-Aldrich (St. Louis, MO) and the 
CeIiTiter-Glo® Luminescent Cell Viability assay was obtained from Promega 
Corporation (Madison, WI). The CytoSelecFM 24-Well Cell Invasion Assay was 
purchased from Cell Biolabs, Inc. (San Diego, CA). 
Cell Culture 
HepG2 cells (clone E6-1, ATCC, Rockville, MO) were cultured in Dulbecco's 
modified eagle medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS), 10 U/ml penicillin, and 1 0 ~g/ml streptomycin. Cells were maintained in an 
incubator at 37°C with humidified 5% CO2 . Cells were plated and incubated 
overnight before treatment, in all experiments. 
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RNA Isolation and Real-Time PCR Analysis 
Total RNA was isolated from cells treated with curcumin, 5-AZA or T8A using 
TRlzol®, according to manufacturer's instructions. For real time PCR, the first 
strand cDNA was synthesized using TaqMan Reverse transcription reagents 
(Applied Biosystems). The reverse transcription was carried out using 1 X 
Taqman RT buffer, 5.5 mM MgCI2 , 500 ~M of each dNTP, 2.5 ~M random 
hexamer, 8 U of RNase inhibitor and 25 U of Multiscribe Reverse Transcriptase 
with 200ng of total RNA. The RT conditions were 10 min at 25°C, 30 min at 48°C 
and 5 min at 95°C. Reactions in which the RNA was omitted served as negative 
controls. Real time PCR was performed with an ABI prism 7500 sequence 
detection system and 8YBR green I dye reagents. 
Reverse transcriptase polymerase chain reaction (RT-PCR) assays were used to 
assess TFPI-2 mRNA levels in HepG2 cells. TFPI-2 and 188 rRNA specific 
primers were purchased from 8uperArray Bioscience Corporation (Frederick, 
MD). The parameter threshold cycle (Ct) was defined as the fraction cycle 
number at which the fluorescence passed the threshold. The relative gene 
expression was analyzed using the 2-AACt method by normalizing with 188 
rRNA gene expression in all the experiments. 
Cell Survival Assays 
The MTT assay and the CeliTiter-Glo® Luminescent Cell Viability assay were 
used to assess cell survival. For the MTT assay, cells were plated in 96 well 
microplates, incubated overnight and treated with curcumin for 24 hours. 
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Treatments were then removed and MTT (1 mg/ml) was added in fresh OM EM 
(100 Ill/well). After incubation at 37°C with humidified 5% CO2 for 1-3 hours, MTT 
lysis buffer (100 Ill/well) was added. The cells were further incubated overnight 
for complete lysis. Cell viability was quantified colorimetrically by measuring 0.0. 
at 570 nm. The CeliTiter-Glo® Luminescent Cell Viability assay was used to 
determine the number of viable cells based on the amount of ATP present. 
Briefly, 10,000 cells/1001l1 per well were plated in 96 well plates. After treatment 
with different concentrations of curcumin (6.25 to 50 11M) for 24 hours, an equal 
volume (100111) of CeIiTiter-Glo® reagent was added to each well. Plates were 
incubated at room temperature for 10min to allow complete cell lysis and 
stabilization of luminescence. The Luminescent signal (RLU) was measured by 
Orion luminometer. 
Cell Invasion Assay 
The CytoSelect™ 24-Well Cell Invasion Assay was performed as per 
manufacturer's instructions. Briefly, a suspension of 1 x 106 cells/ml was prepared 
in serum free media and 300 III of this suspension was placed in the upper 
chamber on the rehydrated membrane. 500 III of culture medium with 10%fetal 
bovine serum (chemoattractant) was placed in the lower chamber. The chamber-
insert assembly was allowed to incubate for at 37°C in 5% CO2 atmosphere. 
After 24 hours, the non-invasive cells were removed, the inserts stained, washed 
and allowed to air dry. Each insert was then incubated in Extraction Solution on 
12 
an orbital shaker at room temperature. 0.0. was measured using a colorimetric 
plate reader. 
Chromatin Immunoprecipitation (ChiP) and gChlP PCR analysis 
The ChiP assay was conducted using the ChiP assay kit according to the 
manufacturer's instructions (Millipore, Billerica, MA). Briefly, 10 X 106 cells were 
crosslinked with 1 % formaldehyde- 1 X-glycine and lysed in lysis buffer 
containing protease inhibitor cocktail. Enzymatic digestion of DNA was 
performed as per manufacturer's protocol (EZ-Zyme Magna CHIP KIT) to 
produce chromatin fragments of 100-166 bp. ChiP antibody directed against 
acetyl-histone H3 (Lys9, 14) (Millipore, Billerica, MA), was used for 
immunoprecipitation. The Iysates were incubated overnight with antibody, 
following which the antibody/protein complexes were immunoprecipated using 
magnetic beads. Successive washes were performed with low salt, high salt, LiCI 
and Tris EDTA (TE) wash buffers. After reverse crosslinking and purification, 
pure DNA was eluted in elution buffer (1 % SDS, 0.1 M NaHC03). qChIP-PCR 
was performed using the ABI Prism 7500 Sequence Detection System. ChIP-
PCR primers designed for two regions of the TFPI-2 promoter were used and 
their sequences are as follows: 
ChiP TFPI-2 (I) LP 
RP 
ChiP TFPI-2 (II) LP 
RP 
GGCTTCTTTACAGCGCAATC 
ACCTGCCTCCCAAACTTTCT 
ACAGTCCCCGTGCATGAAT 
GCAAGGCGTCCGAGAAAG 
13 
Data was analyzed as Differential Occupancy Fold Change. ChIP-qPCR results 
were calculated by llllCt method (since all Ct values for a binding site are 
determined from the same qPCR assay) where each ChiP DNA fractions Ct 
value was normalized to the Input DNA fraction Ct value using llCt [normalized 
ChiP] = (Ct [ChiP] - (Ct [Input] - Log2 (Input Dilution Factor))). The difference 
between the normalized experimental sample (S2) and the control sample (S1) 
ChiP fraction Ct values (second llllCtt) was determined using llllCt [S2-S1] = 
llCt [S2: normalized ChiP] - llCt [S1: normalized ChiP]. 
Bisulfite treatment and methyl-specific peR 
DNA was extracted from untreated and curcumin-treated cells using the DNeasy 
tissue kit and DNA samples were treated with bisulfite (EZ DNA methylation Gold 
Kit from Zymo) following the manufacturer's protocol. Human un methylated DNA 
(Qiagen) and human methylated DNA (Active Motif) were used as controls. The 
bisulfite-converted samples and controls were then amplified with primer pairs 
specific for bisulfite converted methylated DNA and un methylated DNA .The PCR 
reaction uses 10 ng of the bisulfite treated DNA in a 25 III reaction. Standard 
PCR conditions were employed at an optimized annealing temperature. The 
products were analyzed on a 1.4% agarose gel. The methylation-specific primer 
sets have been derived from experiments performed by Glockner et. al.19 and 
have been tested in our laboratory. The primer set most sensitive to methylation 
differences at positions -93 and -32 (with respect to the TSS) of the TFPI-2 
promoter was used, and the primer sequences for this set are shown below. 'M' 
14 
stands for the methylated DNA-specific primer and 'U' stands fot the 
un methylated DNA-specific primer: 
TFPI2(Glockner)-M(1 )-L CGGCGGGGTGATAGTTTTC 
TFPI2(Glockner)-M(1 )-R CAAACGACCCGAATACCCGCTTTATACG 
TFPI2(Glockner)-U(1 )-L GTGGTGGGGTGATAGTTTTTG 
TFPI2(Glockner)-U(1 )-R CCAAACAACCCAAATACCCACTTTATACA 
Table (1) Methyl-specific Real-Time peR primers for a single 
region of the TFPI-2 promoter 
Statistical Analysis 
Data are presented as means± SO for the indicated number of 
independently performed experiments. Student's t-test and one-way ANOVA with 
Tukey's multiple comparison test were used for the determination of statistical 
significance. P<O.05 was considered significant. 
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CHAPTER III 
RESULTS 
Curcumin reactivates TFPI-2 in HepG2 cells 
TFPI-2 is an important tumor suppressor gene that is significantly 
underexpressed in most HCC cell lines and primary HCCs. Hence, this gene 
likely plays a key role in the development and establishment of HCC. We 
therefore examined whether treatment with curcumin affects the expression of 
this critical tumor suppressor in HepG2 cells 
HepG2 cells were plated at a density of 0.5 x 106 cells/ml and incubated 
overnight under standard conditions. The cells were then treated with 25 11M 
curcumin for 24 hours and RNA was obtained as described earlier, for RT-PCR 
analysis. 
Curcumin induced a robust expression of TFPI-2 at 24 hours (fig. 3). 
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Fig. 3 Curcumin-induced TFPI-2 expression in HCC cells. 
HepG2 cells were left untreated (UT) or treated with curcumin (25 ~M) for 24 
hours. TFPI-2 mRNA expression is normalized to 18S rRNA expression and 
shown as fold over untreated. Data is presented as mean ± SO, n=3; * p<O.05 
when compared to UT 
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TFPI-2 is under epigenetic control in HepG2 cells 
It has been shown in previous studies that TFPI-2 is frequently repressed 
in HCC cells by epigenetic mechanisms such as DNA methylation and histone 
deacetylation. We examined the epigenetic regulation of TFPI-2 in HepG2 cells 
using two known epigenetic modulators, 5-Aza-2'deoxycytidine (5-AZA) and 
Trichostatin A (TSA). 5-AZA is a DNA methyltransferase (DNMT) inhibitor and 
functions as a demethylating agent. TSA is a histone deacetylase (HDAC) 
inhibitor and allows acetylation of histone residues. 5-AZA and TSA thus, 
promote transcriptionally permissive epigenetic states, by causing CpG island 
demethylation and histone acetylation, respectively, at promoters of 
epigenetically regulated genes. 
Both 5-AZA and TSA derepressed TFPI-2 leading to the induction of gene 
expression, demonstrating that TFPI-2 is indeed controlled by histone acetylation 
and DNA methylation in HepG2 cells (fig. 4). In comparison to 5-AZA, TSA 
induced TFPI-2 expression to a greater extent, suggesting that histone 
acetylation likely plays a predominant role in regulating the transcriptional 
induction of TFPI-2 gene. Further experiments at longer time pOints are required 
to completely characterize the effects of these agents. 
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Fig. 4 TFPI-2 is epigenetically regulated in HepG2 cells 
. 12HR 
. 24HR 
HepG2 cells were left untreated (UT) or exposed to 5-Aza-2'deoxycytidine 10 11M 
(5-AZA) or Trichostatin A 300 ng/ml (T8A) and TFPI-2 mRNA expression was 
examined at 12 and 24 hours by RT-PCR analysis. TFPI-2 mRNA expression 
was normalized to 188 expression and shown as fold over untreated. 
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Curcumin increases histone H3 acetylation at the TFPI-2 promoter 
Since TFPI-2 is found to be epigenetically silenced in HepG2 cells, we 
hypothesized that curcumin utilizes epigenetic mechanisms to derepress the 
gene. Curcumin likely modifies or reverses the transcriptionally repressive 
epigenetic state of the TFPI-2 promoter. To test this hypothesis, we first 
examined the acetylation status of the histone H3 at the TFPI-2 promoter using 
the Chromatin Immunoprecipitation (ChiP) assay. The ChiP technique allows for 
investigation of DNA-protein interactions at the regions of interest in a gene 
promoter. We designed primers that would specifically amplify TFPI-2 gene 
promoter regions that have binding sites for transcription factors such as AP-1 , 
SP-1 and Egr-1 , which are relevant for TFPI-2 gene expression . As shown in fig . 
5, Region I is closer to the transcription start site (TSS) and covers binding sites 
for AP-1 , SP-1 and Egr-1. Region II is further away from the TSS and covers an 
area with several binding sites for AP-1 . 
-
c:: 
o 
~ 
CI> 
a: 
LI SP-I binding site ~ Egr-l bind ing site 
I AP -I binding Site 
Fig.5 Schematic illustration of the TFPI-2 gene and the regions amplified by 
the ChIP primers (Regions I and II) 
TIS, transcription initiation site; TSS, translation start site; TSC, translation stop 
codon; TTS, transcription termination site. Modified from Chand HS et al.15 
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In this study, we investigated whether curcumin induces changes in the 
histone H3 acetylation at the TFPI-2 promoter, that are relevant for the regulation 
of transcription. Specifically, histone H3 acetylation at Iysines 9 and 14 (H3Ac) 
was examined. This modification is transcriptionally permissive in the promoter 
region and represents 'open chromatin'. Cells were plated and treated with 
curcumin as described in earlier experiments. At 24 hours, the cells were fixed 
with formaldehyde, enzyme digested, and immunoprecipitated with anti-H3Ac 
antibody. DNA obtained after immunoprecipitation was reverse cross-linked and 
amplified with the RT-PCR primers mentioned above (methods). TSA, being an 
HDAC inhibitor, was used as a control in these experiments. 
8 
7 
..... 6 
=> 
~ 5 Q) 
> 4 o 
32 3 
~ 2 
1 
o 
H3Ac at TFPI-2 Promoter region I 
UT Cur 25 TSA 
Fig.6 Curcumin increases histone H3 acetylation at the TFPI-2 promoter 
(Region I) 
Cells were left untreated (UT) or treated with curcumin (25 11M) or TSA (300 
ng/ml) for 24 hours. Chromatin was collected and ChiP RT-PCR was performed 
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for detection of H3Ac at Region I of the TFPI-2 promoter. The data is a 
representation of three independent experiments. 
4.5 
4 
.... 3.5 
::> 3 
... 
~ 2.::; 
o 2 
"C 
"0 1.5 
u.. 1 
0.5 
o 
H3Ac at TFPI-2 Promoter region II 
UT Cur25 TSA 
Fig.7 Curcumin increases histone H3 acetylation at the TFPI-2 promoter 
(Region II) 
Cells were left untreated (UT) or treated with curcumin (25 11M) or TSA (300 
ng/ml) for 24 hours. Chromatin was collected and ChiP RT-PCR was performed 
for detection of H3Ac at Region II of the TFPI-2 promoter. The data is a 
representation of three independent experiments. 
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epG island methylation at nucleotide positions -93 and -32 of the TFPI-2 
promoter is unaffected by curcumin 
Another epigenetic mechanism that contributes to silencing of genes is 
hypermethylation of the cytosines of the CpG sites in gene promoter regions. 
TFPI-2 promoter methylation has been detected in 80% of HCC cell lines and 
47% of human HCCs in a study by Wong et. a1. 9. Aberrant promoter methylation 
has also been shown to correlate with silencing of TFPI-2 in gastric and 
pancreatic tumors. Hence, it is important to examine the effect of curcumin on the 
methylation CpG sites in the TFPI-2 promoter. 
Bisulfite conversion of DNA and methyl-specific RT -PCR was used to 
examine the methylation status of CpG sites at nucleotide positions -93 and -32 
of the TFPI-2 promoter, as described earlier in the methods chapter. Completely 
methylated human DNA and completely unmethylated human DNA were used as 
controls. The TFPI-2 promoter was found to be mostly unmethylated at the sites 
investigated by the primer set used as indicated by the faint band of methylated 
DNA. Further, there was no observable difference in the faint methylated DNA 
band after treatment with (25 11M) curcumin for 24 hours (fig. 8) 
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Fig. 8 TFPI-2 is mostly unmethylated at nucleotide positions -93 and -32 in 
the promoter region 
Cells were left untreated (UT) or treated with curcumin (25 11M) for 24 hours. 
DNA was collected, bisulfite converted and amplified by methyl-specific PCR. 
Methyl-specific primer sets for a single site in the TFPI-2 promoter were used. 
M = Human methylated DNA control , U = Human unmethylated DNA control 
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Curcumin reduces cell invasiveness of HepG2 cells 
TFPI-2 is a matrix-associated Kunitz-type serine proteinase inhibitor, and 
plays an important role in normal extracellular matrix (ECM) remodeling. The 
proteinases inhibited by TFPI-2 in the ECM are not known with certainty. 
However, studies have shown that TFPI-2 inhibits plasmin in vitro and most likely 
in vivo. Recent reports have also demonstrated that TFPI-2 probably inhibits 
matrix metalloproteinases directly in the ECM. Loss of TFPI-2 thus allows for 
degradation of the ECM, which is a critical step in the process of tumor invasion 
and spread. 
In order to study the effect of curcumin on cellular invasiveness in HCC, 
we performed a cell invasion assay. HepG2 cells were plated, treated with 15 j.1M 
curcumin for 24 hours and allowed to pass through a rehydrated basement 
membrane as per manufacturer's protocol (see methods). Curcumin reduced cell 
invasion across the membrane, as shown by the stained inserts and by 
colorimetric quantification in fig. 9. 
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Figs. 9 (a) and (b) Curcumin reduces cell invasiveness in HepG2 cells 
Cells were left untreated (UT) or treated with 15 11M curcumin and allowed to 
invade a rehydrated basement membrane in the cell invasion assay. Staining of 
invasive cells is shown in fig. 9 (a). The invaded cells were then collected, lysed 
and a colorimetric quantification was performed, as shown in fig. 9 (b). 
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Curcumin reduces HepG2 cell survival 
Restoration of TFPI-2 in tumors inhibits cell proliferation and 
angiogenesis, besides reducing cellular invasiveness9. Ectopic overexpression of 
TFPI-2 has also been shown to reduce cell growth in HCC cell lines9 . TFPI-2 
triggered apoptosis in a glioblastoma cell line, probably via a caspase-mediated 
mechanism23• 
We examined the effects of curcumin on cell survival in HepG2 cells using 
two assays - the MTT assay and the CeliTiter-Glo® Luminescent Cell Viability 
assay. The MTT assay measures the activity of enzymes that reduce MTT to 
purple formazan, and thus, is a measure of viable and active cells. Compared 
with untreated cells, curcumin-treated cells demonstrated reduced cell viability in 
the MTT assay at 24 hours (fig. 10). The CeliTiter-Glo® Luminescent Cell 
Viability assay is a homogeneous method to determine the number of viable cells 
in culture based on quantification of the ATP present, which signals the presence 
of metabolically active cells. Curcumin led to a significant reduction in ATP 
production between the concentrations of 12.5 and 50 11M. Moreover, a dose-
dependent decrease in cell viability between the concentration range of 12.5 and 
35 11M was observed (fig. 11). 
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Fig. 10 Curcumin displays cytotoxicity of HepG2 cells 
Cells were left untreated (UT) or treated with curcumin (15 and 25 11M) for 24 
hours and the MTT assay was performed. Data is presented as mean ± SO, n=3, 
* p<0.05 when compared to UT 
ATP Cell Viability Assay 
140000 
lLUUUU 
'" 
100000 
.... 
'c 
:::l 80000 
<II 
> 
'z 60000 
.!2 
<II 
~ 40000 
20000 
0 
UT Cur-6.2SuM Cur-12 .SuM Cur-2SuM Cur-3SuM Cur-SOuM 
Fig.11 Curcumin reduces cell viability of HepG2 cells 
Cells were left untreated (UT) or treated with curcumin (6.25 to 50 11M) for 24 
hours and the CeIiTiter-Glo® Luminescent Cell Viability assay was performed. 
Data is presented as mean ± SEM, n=2; **p<0.01, *** p<0.0001 when compared 
to UT. a, b = p<0.01 
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CHAPTER IV 
SIGNIFICANCE AND CLINICAL RELEVANCE 
All the current therapeutic options for the management of HCC have 
proven inadequate and do not offer satisfactory outcomes. There continues to be 
an acute need for effective therapies. Moreover, the need is getting increasingly 
bigger with the rapidly rising incidence of this highly lethal cancer. Combinatorial 
therapy is the cornerstone of most cancer therapy regimens today. Even in the 
case of HCC, combination therapy or adjuvant chemotherapy appears to be the 
most promising option for effective control. Adjuvant chemotherapy aimed at 
epigenetic modulation may afford even more benefit, given that epigenetic 
modifications playa role in HCC pathogenesis33 . Curcumin has the potential to 
be an effective adjuvant chemotherapeutic agent, and could possibly enhance 
results of traditional chemotherapy through its unique mechanism of action. 
Along with present chemotherapies that mostly aim at tumor control by inhibition 
of DNA synthesis, derepression of critical silenced tumor suppressor genes, 
namely TFPI-2, by curcumin may provide more effective inhibition of tumor 
progression and metastasis. Adjuvant curcumin therapy will allow for reduction of 
dose of the more toxic anti-cancer drugs33. Moreover, as it is a natural compound 
with no side-effects or toxicity to normal cells, curcumin is not expected to cause 
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any toxic side-effects of its own. Several groups are currently working on the 
formulation of effective drug delivery systems for the administration of curcumin. 
In our future studies, we propose to use liposome encapsulated curcumin in an in 
vivo rat HCC model to improve the bioavailability of curcumin. With a well-
elucidated mechanism of action in relation to TFPI-2 and an improved delivery 
system, curcumin could offer tremendous benefit to HCC patients as well as 
persons at risk for HCC development. The low cost and non-existent side-effect 
profile of curcumin only make it more promising as an ideal adjuvant 
chemotherapeutic drug. 
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CHAPTER V 
FUTURE STUDIES 
In further studies with curcumin and TFPI-2, we will investigate other 
epigenetic modifications that may be involved in curcumin-induced TFPI-2 
reactivation. To this end, we will study histone H3 tri-methylation at lysine 4 
(H3K4Me3), which denotes transcriptionally permissive chromatin. Histone 3 
methylation at Kg and tri-methylation at K27, both of which represent 
transcriptionally repressive states, will also be examined. Also, DNA methylation 
at other sites in the TFPI-2 promoter will be examined using different primer sets. 
Binding of transcription factors and RNA polymerase II will also be studied. To 
assess the contribution of the reactivation of TFPI-2 to the anti-HCC effects of 
curcumin, HepG2 cells will be transfected with siRNA for TFPI-2 and cell survival 
and cell invasion assays will be performed. 
The effects of curcumin on other tumor suppressor genes will also be 
examined in the future. The combinatorial effects of curcumin with current 
chemotherapeutic agents will be assessed, to study a potential 
adjuvant/combinatorial chemotherapeutic role for curcumin. 
Finally, we propose to characterize the in vivo effects of curcumin using 
liposome-encapsulated curcumin in our rat xenograft model of HCC. 
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CHAPTER VI 
SUMMARY 
The goal of our study was to examine the anti-HCC effect of curcumin with 
respect to the derepression of the critical tumor suppressor gene, TFPI-2. 
Curcumin was observed to robustly reactivate TFPI-2 in HepG2 cells. TFPI-2 is 
epigenetically regulated in HCC cells. We therefore examined the epigenetic 
modifications at the TFPI-2 promoter region, specifically histone acetylation and 
DNA methylation as influenced by curcumin. Histone H3 acetylation at the 
transcription factor binding sites of the TFPI-2 promoter region was increased by 
curcumin and correlated with the induction of gene expression. This is the likely 
mechanism by which curcumin reactivates TFPI-2. The TFPI-2 promoter was 
found to be only slightly methylated at the single site investigated in this work and 
was not influenced by curcumin. However, other sites in the TFPI-2 promoter 
region need to be examined to fully characterize the effect of curcumin on CpG 
island methylation. Corresponding to the reactivation of TFPI-2, curcumin also 
induced cell death and reduced cell invasiveness in HepG2 cells. Further studies 
will examine the contribution of the epigenetic reactivation of TFPI-2 towards 
these anti-HCC effects. 
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Given the acute need for novel therapeutic options in the management of 
HCC, these studies have the potential to provide a basis for the development and 
use of curcumin in the clinical setting. 
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